close
Add to watchlist
Micromet Inc (MITI) Healthcare
Micromet, Inc., a biopharmaceutical company, engages in the development and sale of antibodies for the treatment of cancer, inflammation, and autoimmune diseases. The company's products under development pipeline using BiTE antibody technology platform include MT103, which is evaluated in a Phase II clinical trial for the treatment of acute lymphoblastic leukemia and in a Phase I clinical trial for the treatment of non-Hodgkin's lymphoma; and MT110 that is tested in a Phase I clinical trial for the treatment of patients with solid tumors. Its products also include adecatumumab (MT201), a recombinant human monoclonal antibody in Phase Ib clinical trial to treat patients with metastatic breast cancer; and MT293, a humanized anti-metastatic and anti-angiogenic monoclonal antibody in a Phase I clinical trial for the treatment of patients with solid tumors. In addition, the company's pre-clinical stage products include MT203, a human antibody to treat rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; MT228, a product for melanoma; MT204, a humanized antibody to treat rheumatoid arthritis, asthma, acute transplant rejection, uveitis, psoriasis, and multiple sclerosis; MT111 that binds to carcinoembryonic antigen, which is expressed in various solid tumors, including colorectal carcinoma, gastric carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MCSP BiTE antibody to treat melanoma; CD33 BiTE antibody to treat acute myelogenic lymphoma; HER2 BiTE antibody to treat breast cancer; and EGFR BiTE antibody to treat solid tumors. The company has license agreements and collaborations with Biovation Limited; Enzon Pharmaceuticals, Inc.; MedImmune LLC; Merck Serono Biopharmaceuticals S.A.; TRACON Pharmaceuticals, Inc.; Nycomed A/S; and Morphotek, Inc. Micromet, Inc. is headquartered in Bethesda, Maryland.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 11.00 |
| Volume | 0 |
| Volume Avg | (mio) 3.05 |
| 52 Week High | 11.00 |
| 52 Week Low | 4.13 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | 0.00 |
| EPS change Q/Q | -47.06% |
| EPS change Q/Q Yr ago | -60.87% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -169.77% |
| REV change Q/Q | -40.22% |
| REV change Q/Q Yr ago | -12.7% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |